Global Bicalutamide Market Size By Type (Tablets, Capsule), By Application (Single Drug For Prostate Cancer, Combined Chemotherapy For Prostate Cancer), By Region, And Segment Forecasts, 2023 to 2032

The Global Bicalutamide Market was valued at USD 645 million in 2023 and is projected to reach USD 1.01 billion by 2031, growing at a CAGR of 5.9% during the forecast period from 2023 to 2031. Bicalutamide, a non-steroidal anti-androgen, is widely used for the treatment of prostate cancer, which remains one of the most prevalent cancers among men globally. The increasing incidence of prostate cancer, rising awareness of early cancer diagnosis, and the development of advanced combination therapies are key factors driving the market. Moreover, the shift towards oral hormone therapies and the growing geriatric population have further supported the demand for bicalutamide-based treatments.

Drivers:

Rising Prostate Cancer Incidence:

An increasing number of prostate cancer diagnoses worldwide, particularly in developed regions, is a significant driver. Early screening programs and greater awareness have contributed to higher diagnosis rates, creating sustained demand for bicalutamide.

Advancements in Hormonal Therapies:

Ongoing innovations in androgen deprivation therapies and the use of bicalutamide in combination regimens for enhanced effectiveness are expanding its usage. Clinical trials continue to support bicalutamide's role in treating different stages of prostate cancer.

Growing Geriatric Population:

As age is a major risk factor for prostate cancer, the growing aging population globally is expected to increase the patient pool, thereby boosting market demand.

Restraints:

Side Effects and Drug Resistance:

Despite its effectiveness, bicalutamide can cause adverse effects such as gynecomastia, hot flashes, and fatigue. In some cases, long-term use may lead to drug resistance, reducing its therapeutic efficacy.

Availability of Alternative Treatments:

The emergence of newer androgen receptor inhibitors and chemotherapy options, offering higher efficacy or fewer side effects, may limit the market potential of bicalutamide in certain treatment scenarios.

Opportunity:

Emerging Markets and Healthcare Access Expansion:

Developing regions in Asia-Pacific and Latin America are witnessing improved access to healthcare and cancer treatment infrastructure. This expansion presents lucrative opportunities for market players to introduce generic and branded bicalutamide drugs.

Growth in Combination Therapy Research:

Ongoing research into multi-drug regimens and synergistic effects of bicalutamide with other anti-cancer agents opens doors for expanded indications and higher efficacy protocols.

Market by System Type Insights:

Based on system type, the Generic Bicalutamide segment accounted for the largest market share in 2023. The expiration of patents and cost-effectiveness of generic variants have made them more accessible, especially in emerging markets. However, the Branded Bicalutamide segment continues to maintain strong demand in developed countries due to brand loyalty and physician preference, particularly in cases requiring strict dosage adherence and premium patient care.

Market by End-use Insights:

By end-use, Hospitals and Cancer Treatment Centers dominated the market in 2023, driven by a high volume of patient intake, structured treatment protocols, and access to comprehensive care. Retail Pharmacies are projected to witness notable growth during the forecast period, especially in outpatient and follow-up care scenarios where oral medications like bicalutamide are dispensed post-discharge.

Market by Regional Insights:

In terms of geography, North America held the dominant share in 2023 due to high prostate cancer prevalence, advanced healthcare infrastructure, and favorable reimbursement policies. Europe followed closely, benefitting from established cancer care protocols. Meanwhile, the Asia-Pacific region is expected to register the highest growth rate, attributed to rising healthcare spending, aging demographics, and growing public health awareness.

Competitive Scenario:

Key players in the Global Bicalutamide Market include AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Mylan N.V., Cipla Inc., Sun Pharmaceutical Industries Ltd., Novartis AG, Zydus Lifesciences Ltd., Apotex Inc., and Accord Healthcare. These companies are focusing on product portfolio expansion, regional market penetration, and strategic alliances. Notable developments include:

2023: Teva launched a cost-effective generic bicalutamide formulation targeting community clinics in Latin America.

2024: AstraZeneca announced a new clinical trial exploring bicalutamide's efficacy in combination with second-generation AR inhibitors.

2025: Cipla expanded its oncology production facility in India to meet rising export demand for bicalutamide.

Scope of Work – Global Bicalutamide Market

Report Metric Details

Market Size (2023) USD 645 million

Projected Market Size (2031) USD 1.01 billion

CAGR (2023–2031) 5.9%

Key Segments System Type (Generic, Branded), End-Use (Hospitals, Retail Pharmacies), Region (North America, Europe, Asia-Pacific, Latin America, MEA)

Growth Drivers Rising prostate cancer prevalence, aging population, advancements in hormone therapy

Opportunities Expansion in emerging markets, research in combination therapies

Key Market Developments:

Teva launched new generic bicalutamide formulations in emerging markets (2023).

AstraZeneca initiated a combination therapy trial with newer AR inhibitors (2024).

Cipla expanded its oncology drug manufacturing to meet growing global demand (2025).

FAQs:

What is the current market size of the Global Bicalutamide Market?

The Global Bicalutamide Market was valued at USD 645 million in 2023.

What is the major growth driver of the Global Bicalutamide Market?

The rising prevalence of prostate cancer and increasing adoption of oral hormone therapies are major growth drivers.

Which is the largest region during the forecast period in the Global Bicalutamide Market?

North America holds the largest market share due to high disease prevalence and advanced treatment facilities.

Which segment accounted for the largest market share in the Global Bicalutamide Market?

The Generic Bicalutamide segment led the market in 2023 owing to its affordability and wide availability.

Who are the key market players in the Global Bicalutamide Market?

Leading companies include AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Cipla Inc., Mylan N.V., and Novartis AG.